Ingrid Mayer
Faculty Member
Last active: 3/23/2014

  1. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) Clin Cancer Res 20(4): 782-90
    › Primary publication · 24536073 (PubMed) · PMC3962777 (PubMed Central)
  2. Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. Yamaguchi NH, Mayer IA, Malzyner A, de Andrade CJ, Murad AM, Del Giglio A, Alves V (2014) J Gastrointest Oncol 5(1): 57-66
    › Primary publication · 24490043 (PubMed) · PMC3904021 (PubMed Central)
  3. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE (2014) Magn Reson Med 71(4): 1592-602
    › Primary publication · 23661583 (PubMed) · PMC3742614 (PubMed Central)
  4. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF (2013) Cancer 119(13): 2375-82
    › Primary publication · 23575918 (PubMed) · PMC3687009 (PubMed Central)
  5. Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report. Iams W, Beckermann KE, Neff AT, Mayer IA, Abramson VG (2013) Med Oncol 30(2): 568
    › Primary publication · 23564368 (PubMed) · PMC3774143 (PubMed Central)
  6. Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Mayer I (2013) Clin Adv Hematol Oncol 11(4): 217-24
    › Primary publication · 23604238 (PubMed) · PMC3774138 (PubMed Central)
  7. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC (2013) J Clin Oncol 31(14): 1726-31
    › Primary publication · 23569315 (PubMed) · PMC3641695 (PubMed Central)
  8. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC (2013) Clin Cancer Res 19(10): 2723-33
    › Primary publication · 23549873 (PubMed) · PMC3655097 (PubMed Central)
  9. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort. Geisberg CA, Abdallah WM, da Silva M, Silverstein C, Smith HM, Abramson V, Mayer I, Means-Powell J, Freehardt D, White B, Lenihan D, Sawyer DB (2013) J Card Fail 19(1): 10-5
    › Primary publication · 23273589 (PubMed) · PMC3562720 (PubMed Central)
  10. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R, National Comprehensive Cancer Network (2013) J Natl Compr Canc Netw 11(7): 753-60; quiz 761
    › Primary publication · 23847214 (PubMed) · PMC3991132 (PubMed Central)